(CercleFinance.com) – Bristol Myers Squibb announced new long-term follow-up results from two Phase 3 studies evaluating CAMZYOS® (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic hypertrophic obstructive cardiomyopathy (HCM).
The results of the 120-week cumulative analysis of the EXPLORER cohort of the MAVA-LTE study were the subject of an oral presentation at the 2023 Congress of the European Society of Cardiology (ESC).
“The new long-term data presented at the ESC were consistent with the primary analyzes of each study, further underscoring the benefit our first-in-class treatment can bring to patients with symptomatic obstructive HCM,” said Amy Sehnert, MD. , Vice President, Head of Cardiomyopathy and Heart Failure Clinical Development, Bristol Myers Squibb.
“These positive data reinforce the clinical significance of these two Phase 3 trials that led to the approval of CAMZYOS in the United States, European Union and other countries around the world. We are excited to continue exploring the potential of CAMZYOS and remain committed to supporting patients with obstructive HCM worldwide.’
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
